Summary
Biophysical research over the last two decades has revealed that an impressive number of mechanical signals are key regulators of cell behavior. So far, the focus has been on understanding fundamental mechanosensing and transduction mechanisms in health and disease. As increasing numbers of molecular players and signalling pathways are identified, the time has come to utilize this knowledge for diagnosing and treating diseases where mechanical processes play a role. In this proposal, I aim to target integrins to deliver reporter molecules and drugs to cells with a distinct mechanical phenotype. Integrins are transmembrane receptors through which cells can sense, transmit and discriminate biomechanical forces. During cell adhesion and migration, integrins engage with specific ligands in the extracellular matrix and undergo integrin recycling through continuous endo- and exocytosis. This known endocytic pathway, integrin clustering during adhesion and overexpression in disease states has made integrins a prime target for drug delivery. However, the chemical and physical factors governing integrin-mediated uptake of drugs and their intracellular fate are unknown. I propose to utilize molecular force sensor (MFS) technology to deconvolute the key factors in integrin-mediated drug delivery. Using rational protein design, a series of coiled coil MFSs with distinct chemical (charge and hydrophobicity) and physical (mechanical and thermal stability) properties will be produced. The molecular constructs will be appended with the integrin-targeting RGD motif, a fluorescent protein to investigate the intracellular fate and an actin-binding protein as a model drug that may potentially interfere with the cytoskeleton architecture. This MFS-based drug delivery system will enlighten the pivotal factors of integrin-mediated delivery, provide a diagnostic assay for discriminating cells based on their mechanical phenotype and open up the road towards mechano-targeted drug delivery.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101109118 |
| Start date: | 01-09-2024 |
| End date: | 31-08-2026 |
| Total budget - Public funding: | - 183 600,00 Euro |
Cordis data
Original description
Biophysical research over the last two decades has revealed that an impressive number of mechanical signals are key regulators of cell behavior. So far, the focus has been on understanding fundamental mechanosensing and transduction mechanisms in health and disease. As increasing numbers of molecular players and signalling pathways are identified, the time has come to utilize this knowledge for diagnosing and treating diseases where mechanical processes play a role. In this proposal, I aim to target integrins to deliver reporter molecules and drugs to cells with a distinct mechanical phenotype. Integrins are transmembrane receptors through which cells can sense, transmit and discriminate biomechanical forces. During cell adhesion and migration, integrins engage with specific ligands in the extracellular matrix and undergo integrin recycling through continuous endo- and exocytosis. This known endocytic pathway, integrin clustering during adhesion and overexpression in disease states has made integrins a prime target for drug delivery. However, the chemical and physical factors governing integrin-mediated uptake of drugs and their intracellular fate are unknown. I propose to utilize molecular force sensor (MFS) technology to deconvolute the key factors in integrin-mediated drug delivery. Using rational protein design, a series of coiled coil MFSs with distinct chemical (charge and hydrophobicity) and physical (mechanical and thermal stability) properties will be produced. The molecular constructs will be appended with the integrin-targeting RGD motif, a fluorescent protein to investigate the intracellular fate and an actin-binding protein as a model drug that may potentially interfere with the cytoskeleton architecture. This MFS-based drug delivery system will enlighten the pivotal factors of integrin-mediated delivery, provide a diagnostic assay for discriminating cells based on their mechanical phenotype and open up the road towards mechano-targeted drug delivery.Status
SIGNEDCall topic
HORIZON-MSCA-2022-PF-01-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
